To account for patient attrition over time, AEs relevant
to the mechanism of action of SGLT2 inhibitors were
assessed at each point of study extension. A greater number
of hypoglycaemic events were observed in the glipizide arm
than in the dapagliflozin arm at all time points assessed. The
proportion of patients with hypoglycaemic events was lower
in the dapagliflozin group than in the glipizide group (5.4
vs 51.5% at 208 weeks). In the glipizide group, 3 patients
experienced a major hypoglycaemic event and 7 discontinued
treatment because of hypoglycaemia, compared with none in
the dapagliflozin group (Table 3).